title: Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.
abstract: High grade uterine sarcoma and recurrent endometrial carcinoma are aggressive cancers with limited treatment options, resulting in a poor prognosis. In this research we focused in the first place on the detection of a highly immunogenic tumour-associated antigen Wilms' tumour gene 1 (WT1) in uterine tumours. We were able to reveal its overexpression in the tumour cells of high grade sarcomas and carcinosarcomas . Moreover, patients with WT1 positive tumours had a significantly worse prognosis than patients who were WT1 negative. For carcinomas, WT1 was present in only a minority of tumour cells, but in the majority of intratumoural blood vessels. Small blood vessels in the normal tissue surrounding the carcinoma were also WT1 positive, suggesting a role for WT1 in angiogenesis. WT1 was hardly expressed or absent in the non-tumour or benign tumoural uterus (myoma, polyp). The next step was to develop a targeted treatment against WT1. We opted for dendritic cell (DC) based immunotherapy. Nevertheless a basal expression of WT1 in monocytes and in vitro cultured unloaded DC was observed, the electroporation of in vitro cultured DC with WT1-mRNA resulted in a higher expression of WT1 by the DC. WT1-mRNA loaded DC were used for in vivo stimulations of T cells, resulting in the rise of WT1-specific T cells and a transient molecular response (decrease of CA125) in an end stage endometrial carcinoma patient. No toxic side effects were reported. Future in vivo research, carried out in a phase I clinical trial in our center, will reveal the ability of this new therapy to induce an immunological and possible clinical response in WT1 positive uterine cancer patients.
authors.affiliation: Department of woman and child, UZ Leuven, Leuven, Belgium and Immunotherapy Platform Leuven (ITPL), UZ Leuven, Leuven, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Coosemans
keywords: Dendritic cells; WT1; Wilms’ tumour gene 1; immunotherapy; uterine tumour
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5323-37
references.pmid: 19723653
references.citation: Biochem Biophys Res Commun. 2005 Jan 28;326(4):836-43
references.pmid: 15607745
references.citation: Histopathology. 2009 Feb;54(3):384-7
references.pmid: 19236519
references.citation: Eur J Cancer. 2007 Jul;43(10):1630-7
references.pmid: 17531467
references.citation: Lancet. 2005 Aug 6-12;366(9484):491-505
references.pmid: 16084259
references.citation: Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8132-7
references.pmid: 9223327
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
references.pmid: 16467102
references.citation: J Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7
references.pmid: 15287461
references.citation: Gynecol Oncol. 2002 Apr;85(1):165-9
references.pmid: 11925138
references.citation: Int J Gynecol Pathol. 2004 Jul;23(3):241-7
references.pmid: 15213600
references.citation: Physiology (Bethesda). 2005 Feb;20:54-9
references.pmid: 15653840
references.citation: CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
references.pmid: 10200776
references.citation: Expert Rev Mol Med. 2007 May 24;9(14):1-17
references.pmid: 17524167
references.citation: Int J Gynecol Cancer. 2011 Feb;21(2):302-8
references.pmid: 21734473
references.citation: Genes Dev. 2005 Nov 1;19(21):2631-42
references.pmid: 16264195
references.citation: Anticancer Res. 2010 Sep;30(9):3709-14
references.pmid: 20944158
references.citation: Neuro Oncol. 2009 Oct;11(5):529-42
references.pmid: 19336528
references.citation: Oncogene. 2008 Jun 12;27(26):3662-72
references.pmid: 18212735
references.citation: Histopathology. 2005 Apr;46(4):468
references.pmid: 15810962
references.citation: Development. 2005 Mar;132(6):1327-36
references.pmid: 15716344
references.citation: Int J Gynecol Cancer. 2001 May-Jun;11(3):218-23
references.pmid: 11437928
references.citation: Cell. 2001 Aug 24;106(4):391-4
references.pmid: 11525724
references.citation: Gynecol Oncol. 2008 Dec;111(3):502-8
references.pmid: 18929401
references.citation: Hum Mol Genet. 2002 Mar 15;11(6):651-9
references.pmid: 11912180
references.citation: Br J Cancer. 2004 Nov 1;91(9):1656-62
references.pmid: 15477864
references.citation: Int J Cancer. 2002 Jul 20;100(3):297-303
references.pmid: 12115544
references.citation: Leukemia. 2007 May;21(5):868-76
references.pmid: 17361230
references.citation: Cancer Immunol Immunother. 2005 Apr;54(4):372-82
references.pmid: 15692847
references.citation: Lancet Oncol. 2009 Dec;10(12):1188-98
references.pmid: 19959075
references.citation: Cancer. 2006 May 15;106(10):2233-40
references.pmid: 16607650
references.citation: Gynecol Oncol. 2010 Feb;116(2):222-33
references.pmid: 19959212
references.citation: J Neurooncol. 2007 Sep;84(2):131-40
references.pmid: 17361330
references.citation: Pediatr Dev Pathol. 2005 Jul-Aug;8(4):427-34
references.pmid: 16220232
references.citation: Gynecol Oncol. 2004 Aug;94(2):449-55
references.pmid: 15297187
references.citation: Clin Cancer Res. 2008 May 15;14(10):3098-104
references.pmid: 18483377
references.citation: Cancer Sci. 2003 Aug;94(8):712-7
references.pmid: 12901797
references.citation: Brain Pathol. 2009 Oct;19(4):694-712
references.pmid: 19744041
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: FASEB J. 2003 Jul;17(10):1364-6
references.pmid: 12738801
references.citation: Nature. 2007 Sep 27;449(7161):419-26
references.pmid: 17898760
references.citation: Blood. 1997 Nov 15;90(10):4230-2
references.pmid: 9354696
references.citation: Genes Chromosomes Cancer. 1995 Dec;14(4):313-5
references.pmid: 8605121
references.citation: Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):164-9
references.pmid: 11396634